Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities

Alberto Vogrig^{1

2

3}, Sergio Muñiz-Castrillo^{1

2

3}, Jérôme Honnorat^{1

2

3}

Affiliations

¹ National Reference Center for Paraneoplastic Neurological Syndromes, Lyon Civil Hospices, Neurological Hospital, Lyon, France.
² Synatac Team, NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon, France.
³ University Claude Bernard Lyon 1, University of Lyon, Lyon, France.

Comment

Alberto Vogrig et al. Ann Neurol. 2020 Jul.

. 2020 Jul;88(1):199-200.

doi: 10.1002/ana.25764. Epub 2020 May 19.

Alberto Vogrig^{1

2

3}, Sergio Muñiz-Castrillo^{1

2

3}, Jérôme Honnorat^{1

2

3}

¹ National Reference Center for Paraneoplastic Neurological Syndromes, Lyon Civil Hospices, Neurological Hospital, Lyon, France.
² Synatac Team, NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon, France.
³ University Claude Bernard Lyon 1, University of Lyon, Lyon, France.

No abstract available

Comment in

Reply to "Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities".
Dubey D, Guidon A. Dubey D, et al. Ann Neurol. 2020 Jul;88(1):200-201. doi: 10.1002/ana.25763. Epub 2020 May 22. Ann Neurol. 2020. PMID: 32368808 No abstract available.

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum.
Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC. Dubey D, et al. Ann Neurol. 2020 May;87(5):659-669. doi: 10.1002/ana.25708. Epub 2020 Mar 10. Ann Neurol. 2020. PMID: 32086972